[Expression of cyclophilin A/CD147 in carotid atherosclerotic plaque and the intervention of atorvastatin].
OBJECTIVE
To explore the expression of CyPA and CD147 in rabbit models of vulnerable carotid atherosclerotic plaque and the therapeutic effect of atorvastatin.


METHODS
Twenty-four male New Zealand rabbits were randomly divided into 3 groups. Eight rabbits were served as a normal diet group (Group A), and the remaining 16 rabbits underwent balloon-induced endothelial injury in the right carotid artery and thereafter were fed on high-cholesterol diet (1% cholesterol) for 12 weeks, then they were divided into 2 groups: a AS group (Group B), an atorvastatin group [Group C, 2.5 mg/(kg.d)]. 4 weeks later, plaque disrupture was triggered by China Russell's viper venom and histamine. Serum levels of TC, TG, LDL-C and HDL-C were measured at different timepoint. The damaged carotid arteries were collected to undergo pathological examination. The macrophage, expression of CyPA and CD147 were detected by immuno-histochemical analysis, and the mRNA levels of CyPA and CD147 were examined by reverse transcription polymerase chain reaction (RT-PCR).


RESULTS
Compared with the Group A, the serum levels of TC and LDL-c in the Group B and Group C were significantly increased (all P<0.01). Compared with the Group B, the serum levels of TC and LDL-c in the Group C were reduced significantly after atorvastatin intervention for 4 weeks (all P<0.01). The plaques disruption and thrombosis occurred in 4 out of the 6 rabbits in the Group B, while only 1 rabbit demonstrated plaques disruption and thrombosis in the Group C. Compared with the Group B, the levels of CyPA, CD147 and macrophage in carotid atherosclerotic plaque in the Group C were decreased significantly (all P<0.01).


CONCLUSIONS
The up-regulation of CyPA and CD147 may be involved in pathogenesis of vulnerable carotid atherosclerotic plaque. Atorvastatin could stabilize the plaque through inhibiting the CyPA and CD147 expression.
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515; Department of Neurology, Hunan Provincial People's Hospital, Hunan Normal University, Changsha 410005, China.
Juhua
J
Gao
Department of Neurology, Hunan Provincial People's Hospital, Hunan Normal University, Changsha 410005, China.
Xiaoping
X
Gao
Department of Neurology, Hunan Provincial People's Hospital, Hunan Normal University, Changsha 410005, China.
Zhihong
Z
Zhao
Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Suyue
S
Pan
D000818:Animals; D000069059:Atorvastatin / Q000494:pharmacology*; D051926:Basigin / Q000378:metabolism*; D017536:Carotid Artery, Common / Q000473:pathology; D002784:Cholesterol / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D021984:Cyclophilin A / Q000378:metabolism*; D008264:Macrophages / Q000166:cytology; D008297:Male; D058226:Plaque, Atherosclerotic / Q000188:drug therapy* / Q000378:metabolism*; D011817:Rabbits; D011897:Random Allocation; D013927:Thrombosis / Q000473:pathology; D014280:Triglycerides / Q000097:blood
D002791:Cholesterol, Dietary; D014280:Triglycerides; D051926:Basigin; D002784:Cholesterol; D000069059:Atorvastatin; D021984:Cyclophilin A